52605-98-8

Usage

Uses

Used in Organic Synthesis:
5-Bromo-2,3-dimethoxypyridine is used as a key intermediate in organic synthesis for the production of various compounds. Its reactivity and unique structure allow for the creation of a wide range of chemical products.
Used in Pharmaceutical Industry:
5-Bromo-2,3-dimethoxypyridine is used as a building block in the pharmaceutical industry for the development of new drugs. Its potential applications in medicinal chemistry and drug development are attributed to its ability to be modified to create compounds with specific biological activities.
Used in Agrochemical Industry:
5-Bromo-2,3-dimethoxypyridine is used as a precursor in the agrochemical industry for the synthesis of various agrochemicals. Its unique properties make it suitable for the development of new agrochemical products.
Used in Specialty Chemicals Industry:
5-Bromo-2,3-dimethoxypyridine is used as a component in the production of specialty chemicals. Its versatility and reactivity contribute to the development of specialized chemical products.
Safety Precautions:
It is important to handle 5-Bromo-2,3-dimethoxypyridine with care due to its potential hazards, including flammability and toxicity. Proper safety measures should be taken during its use and storage to minimize risks.

InChI:InChI=1/C7H8BrNO2/c1-10-6-3-5(8)4-9-7(6)11-2/h3-4H,1-2H3

Upstream product

• 52605-97-7 2,3-dimethoxypyridine 
• 52605-96-6 2-chloro-3-methoxypyridine 
• 6636-78-8 2-chloro-3-hydroxypyridine 
• 1142191-57-8 2,5-dibromo-3-methoxy-pyridine 
• 124-41-4 sodium methylate 
• 20265-37-6 3-methoxy-2-nitropyridine 
• 10201-71-5 3-methoxypyridin-2-amine 
• 42409-58-5 5-bromo-3-methoxy-pyridin-2-amine 
• 67-56-1 methanol 
• 286947-03-3 5-bromo-2-chloro-3-methoxy-pyridine 
• 141-52-6 sodium ethanolate 
• 78156-39-5 3-bromo-5-methoxypyridine 1-oxide 
• 2402-99-5 3,5-dibromopyridine-N-oxide 

Downstream Products

• 52605-99-9 5-formyl-2,3-dimethoxypyridine 
• 1083168-92-6 2,3-dimethoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine 
• 1112851-31-6 5,6-dimethoxypyridine-3-carbonitrile 
• 1171919-88-2 2,3-dimethoxy-5-[(trimethylsilyl)ethynyl]pyridine 
• 1253408-56-8 C₂₄H₂₈N₆O₄S 
• 1417710-34-9 2,3-dimethoxy-5-[(E)-2-phenylethenyl]pyridine 
• 1417710-35-0 2,3-dimethoxy-5-(2-phenylethyl)pyridine 
• 1417710-20-3 3-hydroxy-5-(2-methylphenethyl)pyridin-2(1H)-one 
• 1417710-60-1 2,3-dimethoxy-5-[(2-methylphenyl)ethynyl]pyridine 
• 1417710-30-5 5-(benzylsulfanyl)-2,3-dimethoxypyridine 
• 1417709-95-5 5-(benzylsulfanyl)-3-hydroxypyridin-2(1H)-one 
• 76470-34-3 5,6-dimethoxynicotinic acid 

Relevant academic research and scientific papers

Contorted Heteroannulated Tetraareno[a,d,j,m]coronenes

Fused polycyclic aromatic compounds are interesting materials for organic electronics applications. To fine-tune photophysical or electrochemical properties, either various substituents can be attached or heteroatoms (such as N or S) can be incorporated into the fused aromatic backbone. Coronenes and heterocoronenes are promising compounds in this respect. Up until now, the possibilities for varying the attached fused heteroaromatics at the coronene core were quite limited, and realizing both electron-withdrawing and -donating rings at the same time was very difficult. Here, a series of pyridine, anisole and thiophene annulated tetraareno[a,d,j,m]coronenes has been synthesized by a facile two-step route that is a combination of Suzuki-Miyaura cross-coupling and a following cyclization step, starting from three different diarenoperylene dibromides. The contorted molecular π-planes of the obtained cata-condensed tetraarenocoronenes were analyzed by single-crystal X-ray crystallography, and the photophysical and electrochemical properties were systematically investigated by UV/Vis spectroscopy and cyclovoltammetry.

D-AMINO ACID OXIDASE INHIBITORS AND THERAPEUTIC USES THEREOF

The present invention relates to compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: each of A, B, C, D, and E, independently, is C, N, N—H, O, S, or absent is a single bond or a double bond; each of X, Y, and Z, independentl

Nobiletin derivative or pharmaceutically acceptable salt thereof as well as preparation method and application thereof

The invention discloses a nobiletin derivative or a pharmaceutically acceptable salt thereof as well as a preparation method and application thereof. The nobiletin derivative has a structural formula(I) shown in the description, in the formula, R1, R2, R3 and R4 are respectively selected from hydrogen, halogen, hydroxyl, amino, C1-6 substituted or non-substituted alkoxy, a C1-6 substituted or non-substituted ester group, C1-6 substituted or non-substituted alkamino and a C1-6 substituted or non-substituted amide group; R5 is selected from a C3-9 substituted or non-substituted aromatic ring and a C3-9 substituted or non-substituted aromatic heterocyclic ring; and X is selected from O or NR6. The nobiletin derivative or the pharmaceutically acceptable salt thereof, which is disclosed by theinvention, is novel in structure, and in addition, the compound has an excellent inhibition function on P-gp, can be prepared into a P-gp inhibitor, is capable of treating and/or preventing related diseases caused by P-gp, particularly diseases related to tumor drug resistance, or can be mixed and used with other medicines and used as a drug resistance reversal agent, has a high reversion multiple, and is capable of remarkably improving medicine effects of medicines.

Aryl and Arylalkyl Substituted 3-Hydroxypyridin-2(1H)-ones: Synthesis and Evaluation as Inhibitors of Influenza A Endonuclease

Seasonal influenza infections are associated with an estimated 250–500 000 deaths annually. Resistance to the antiviral M2 ion-channel inhibitors has largely invalidated their clinical utility. Resistance to neuraminidase inhibitors has also been observed in several influenza A virus (IAV) strains. These data have prompted research on inhibitors that target the cap-snatching endonuclease activity of the polymerase acidic protein (PA). Baloxavir marboxil (Xofluza), recently approved for clinical use, inhibits cap-snatching endonuclease. Resistance to Xofluza has been reported in both in vitro systems and in the clinic. An X-ray crystallographic screening campaign of a fragment library targeting IAV endonuclease identified 5-chloro-3-hydroxypyridin-2(1H)-one as a bimetal chelating agent at the active site. We have reported the structure–activity relationships for 3-hydroxypyridin-2(1H)-ones and 3-hydroxyquinolin-2(1H)-ones as endonuclease inhibitors. These studies identified two distinct binding modes associated with inhibition of this enzyme that are influenced by the presence of substituents at the 5- and 6-positions of 3-hydroxypyridin-2(1H)-ones. Herein we report the structure–activity relationships associated with various para-substituted 5-phenyl derivatives of 6-(p-fluorophenyl)-3-hydroxypyridin-2(1H)-ones and the effect of using naphthyl, benzyl, and naphthylmethyl groups as alternatives to the p-fluorophenyl substituent on their activity as endonuclease inhibitors.

Discovery of 5″-chloro-n-[(5,6-dimethoxypyridin-2- yl)methyl]-2,2':5',3″-Terpyridine-3'-carboxamide (mk-1064): A selective orexin 2 receptor antagonist (2-sora) for the treatment of insomnia

The field of small-molecule orexin antagonist research has evolved rapidly in the last 15 years from the discovery of the orexin peptides to clinical proof-of-concept for the treatment of insomnia. Clinical programs have focused on the development of antagonists that reversibly block the action of endogenous peptides at both the orexin 1 and orexin 2 receptors (OX1R and OX2R), termed dual orexin receptor antagonists (DORAs), affording late-stage development candidates including Merck's suvorexant (new drug application filed 2012). Full characterization of the pharmacology associated with antagonism of either OX1R or OX2R alone has been hampered by the dearth of suitable subtype-selective, orally bioavailable ligands. Herein, we report the development of a selective orexin 2 antagonist (2-SORA) series to afford a potent, orally bioavailable 2-SORA ligand. Several challenging medicinal chemistry issues were identified and overcome during the development of these 2,5-disubstituted nicotinamides, including reversible CYP inhibition, physiochemical properties, P-glycoprotein efflux and bioactivation. This article highlights structural modifications the team utilized to drive compound design, as well as in vivo characterization of our 2-SORA clinical candidate, 5''-chloro-N- [(5,6-dimethoxypyridin-2-yl)methyl] -2,2':5',3''-terpyridine-3'-carboxamide (MK-1064), in mouse, rat, dog, and rhesus sleep models.

Phenyl substituted 3-hydroxypyridin-2(1H)-ones: Inhibitors of influenza A endonuclease

Inhibition of the endonuclease activity of influenza RNA-dependent RNA polymerase is recognized as an attractive target for the development of new agents for the treatment of influenza infection. Our earlier study employing small molecule fragment screening using a high-resolution crystal form of pandemic 2009 H1N1 influenza A endonuclease domain (PAN) resulted in the identification of 5-chloro-3-hydroxypyridin-2(1H)-one as a bimetal chelating ligand at the active site of the enzyme. In the present study, several phenyl substituted 3-hydroxypyridin-2(1H)-one compounds were synthesized and evaluated for their ability to inhibit the endonuclease activity as measured by a high-throughput fluorescence assay. Two of the more potent compounds in this series, 16 and 18, had IC50 values of 11 and 23 nM in the enzymatic assay, respectively. Crystal structures revealed that these compounds had distinct binding modes that chelate the two active site metal ions (M1 and M2) using only two chelating groups. The SAR and the binding mode of these 3-hydroxypyridin-2-ones provide a basis for developing a new class of anti-influenza drugs.

FSH RECEPTOR ANTAGONISTS

The invention relates to FSH receptor antagonist according to general formula (I) or a pharmaceutically acceptable salt thereof and to a pharmaceutical composition containing the same. The compounds can be used for the treatment and prevention of endometriosis, for the treatment and prevention of pre-menopausal and peri-menopausal hormone-dependent breast cancer, for contraception, and for the treatment of uterine fibroids and other menstrual-related disorders

UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY

Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.

PYRAZOLE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of variou

ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.